Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …

Gene regulatory networks (GRNs) are key determinants of cell function and identity and are
dynamically rewired during development and disease. Despite decades of advancement …

The transcription factor, forkhead box M1 (FOXM1), has been implicated in the natural
history and outcome of newly diagnosed high-risk myeloma (HRMM) and relapsed/refractory …

Multiple Myeloma is an incurable plasma cell malignancy with a poor survival rate that is
usually treated with immunomodulatory drugs (iMiDs) and proteosome inhibitors (PIs). The …

Numerical abnormalities of chromosome 1q (+ 1q21) are common in patients with newly
diagnosed multiple myeloma (MM) but their prognostic impact remains a matter of debate. In …

PBX1 is a critical transcription factor at the top of various cell fate-determining pathways. In
cancer, PBX1 stands at the crossroads of multiple oncogenic signaling pathways and …

The transcription factor PBX1 is regarded as an oncogene in various cancers, but its role in
non-small cell lung cancer (NSCLC) and the detailed mechanism is not known. In the …

Dear Editor, Daratumumab (Dara) and Isatuximab (Isa) are monoclonal antibodies that
target CD38, a glycoprotein highly expressed by plasma cells and Multiple Myeloma (MM) …

Glioma is the most common primary brain tumor, and targeting glioma stem cells (GSCs) has
become a key aspect of glioma treatment. In this study, we discovered a molecular network …

The lack of effective screening and successful treatment contributes to high ovarian cancer
mortality, making it the second most common cause of gynecologic cancer death …